Dynamics of immunoglobulin G subclasses during the first two years of life in Malawian infants born to HIV-positive mothers

Silvia Baroncelli 1*, Clementina Maria Galluzzo 1, Giuseppe Liotta 2, Mauro Andreotti 1, Stefano Orlando 2, Fausto Ciccacci 3, Haswell Jere 4, Richard Luhanga 4, Jean Baptiste Sagno 4, Roberta Amici 1, Maria Cristina Marazzi 5 and Marina Giuliano 1

Abstract

Background: Maternal antibodies are key components of the protective responses of infants who are unable to produce their own IgG until 6 months of life. There is evidence that HIV-exposed uninfected children (HEU) have IgG levels abnormalities, that can be partially responsible for the higher vulnerability to infections in the first 2 years of the life of this population.

This retrospective study aimed to characterize the dynamics in plasma levels of total IgG and their isotypes during the first 2 years of life in HEU infants exclusively breastfed through 6 months of age.

Methods: Total IgG, IgG1, IgG2, IgG3 and IgG4 isotypes, and IgM and IgA plasma concentrations were determined by nephelometric methods in 30 Malawian infants born to HIV-positive women at month 1, 6 and 24 of life.

Results: At 1-month infants had a median concentration of total IgG of 8.48 g/l, (IQR 7.57–9.15), with an overrepresentation of the IgG1 isotype (89.0% of total) and low levels of IgG2 (0.52 g/l, IQR, 0.46–0.65). Total IgG and IgG1 concentrations were lower at 6 months (−2.1 and −1.12 g/dl, respectively) reflecting disappearance of maternal antibodies, but at 24 months their levels were higher with respect to the reported reference values for age-matched pairs. Abnormal isotype distribution was still present at 24 months with IgG2 remaining strongly underrepresented (0.87 g/l, 7.5% of total IgG).

Conclusion: HIV exposure during pregnancy and breastfeeding seems to influence the IgG maturation and isotype distribution that persist in 2-year old infants.

Keywords: Immunoglobulin G, Isotypes, Infants, HIV, Malawi
Background
The process of immunoglobulins development and maturation starts during intrauterine life [1] however, the fetus can not produce IgGs, that are received from the mother in a complex mechanism of selective placental passage (preferential transport occurs for the IgG1 isotype followed by IgG4, IgG3 and IgG2 [2]. Neonates are therefore born with a functional immaturity of the immune system and early protection initially relies on the presence of maternal antibodies [3]. Only after the first months of life will infants start to produce their own IgGs, achieving the full immune competence only in late adolescence [4].

In maternal pathological conditions, such as infections and/or inflammatory status the bidirectional fetal-maternal immune cross-talk, including the passage of IgG from mother to fetus, can be altered with important consequences for offspring’s health [5, 6]. Clinical and epidemiological studies reported evidence that maternal HIV infection can deeply affect the maternal/fetal unit, interfering with the immunomodulatory factors which shape immune maturation in fetuses [7, 8]. Immunological abnormalities have been observed in HIV-exposed uninfected (HEU) children, including defects in CD4+ helper T cells and in immune regulatory function [9], and low responsiveness to vaccination [10]. In particular, maternal transplacental transfer of IgGs is inadequate in HIV-exposed children. In healthy pregnancies, full-term neonates have a cord blood IgG concentration often exceeding the maternal plasma concentration [11], but in HIV infection significant reduction of the IgG child/maternal ratio (CMR) has been observed [12]. Several studies have shown that HEU newborns have lower levels of HbA1c, pertussis-, pneumococcus-, and tetanus-specific antibodies when compared to non-HIV exposed peers [13]. HIV studies on antenatal vaccine programs have also reported impaired passage through the placenta [14–16].

However, while the decreased transplacental passage has been extensively demonstrated, only a few studies have investigated the subsequent development and maturation of total IgG and IgG subclasses in HEU infants. Immunoglobulins have a key role in the response against pathogens and in the development of adequate responses to vaccinations [17] and the determination of their levels can provide useful information on the status of the humoral immune system. IgGs ranges are well established in adult populations from different geographical areas [18], but the reference intervals are still uncertain in infants since many external factors, such as in utero stimuli, genetic and environmental influences, and exposition to pathogens, could impact on the dynamic process of immunoglobulin development and maturation [2, 11, 19]. Because of the limited number of studies reporting the dynamics of IgG levels in African children, there is a need for a better characterization of the immunoglobulin profile in these populations. The present study is therefore aimed to assess the IgG and IgG subclasses levels during the first 2 years of the life of Malawian infants born to HIV+ mothers.

Methods
Study population
The study population included infants enrolled in a cohort study [SMAC (Safe Milk for African Children) study], conducted in Malawi (enrollment: February 2008 – February 2009), and investigating the safety and efficacy of antiretroviral therapy (ART) administration in HIV+ pregnant and lactating women. Study design, clinical details, and antiretroviral strategies have been previously described [20]. The original study did not include a control group. The antiretroviral strategy followed the criteria for treatment in use in Malawi at the time [21]. Naive HIV-positive women with a CD4+ cell count < 350 CD4 cell/μl started ART as soon as possible after the first trimester, with a combination of stavudine (d4T 30 mg twice daily), lamivudine (3TC, 150 mg twice daily) and nevirapine (200 mg twice daily) and continued the same treatment after the end of breastfeeding. For women with a CD4+ cell count > 350 cell/μl ART was started at 25 weeks of pregnancy with zidovudine (ZDV, 300 mg twice daily), lamivudine and nevirapine, according to the DREAM program [22] and was continued until 6 months after delivery (end of breastfeeding period). All infants received a single dose of NVP syrup (2 mg/kg of body weight) within 72 h of birth.

Gestational age information was self-reported by the women, without obstetric ultrasound confirmation. Therefore this information was not considered reliable. We used neonatal weight as a possible surrogate measure, and according to the World Health Organization (WHO) indication, a neonatal weight < 2500 g was considered low birth weight [23].

Inclusion criteria for this substudy were based on the availability of infant plasma samples at the following timepoints: month 1, month 6 (optional), and month 24 (a total of 30 HEU infants). We have also included 5 additional infants, who had acquired HIV infection and had samples available (in the entire population of 300 infants of the SMAC study a total of 8 infants had acquired the infection).

Since their sample availability was incomplete and the timing of infection was different we decided to analyze them separately.

The study was conducted in Blantyre and Lilongwe, within the DREAM (Drug Resource Enhancement against AIDS and Malnutrition) Program of the
Community of S. Egidio, an Italian faith-based non-governmental organization.

Plasma IgG levels and IgG subclasses

Total IgG and IgG subclass plasma levels were determined using IgG total, IgG1, IgG2, IgG3 and IgG4 reagents (Siemens, Siemens Healthcare Diagnostics) and read by automatized nephelometry (BN ProSpec® System analyzer, Siemens Healthcare Diagnostics). Total IgA and IgM levels were also determined using the same methodology.

Since no IgGs reference intervals were available from healthy infants born in the same geographic/socioeconomic setting of our study, we contextualized our results reporting IgG maturation trend from recent studies on healthy infants from other countries/regions. IgGs reference intervals from other studies were merely used to depict physiological age-specific changes in IgG levels, and no statistical analyses were performed.

Statistical analysis

The SPSS software version 25 (IBM Corp, 2017, Armonk, NY, USA) was used for statistical analyses. Results are presented as medians with interquartile range (IQR) and percentages. Longitudinal differences were determined using the Wilcoxon Signed Rank Test and Spearman’s correlation coefficient was used for the correlation analysis between quantitative variables. Differences were considered statistically significant when \( p < 0.05 \).

Results

Population characteristics

All infants were delivered vaginally. Their mothers’ characteristics are reported in Table 1. The median age was 28 years, and the median ART duration during pregnancy was 10 weeks. During the study, good adherence to the drug strategy was observed in women, and 6 months postpartum rate of viral suppression (<400 HIV-RNA copies/ml) was over 90%.

Infants were exclusively breastfed for 6 months when all mothers received ART. IgG and IgG isotype levels were determined in 1, 6 and 24-month old infants. The results are reported in Fig. 1 and Table 2.

Immunoglobulins maturation in infants

At 1 month the median IgG total level was 8.48 g/l (IQR: 7.57–9.15) and the IgG1 isotype level (7.27 g/l, IQR: 6.65–8.18) accounted for almost 90% of the total IgG. IgG2 levels (median: 0.52 g/l, 6.6% of total IgG) were below 1.0 g/l in all but one infant. The levels of total IgG were inversely correlated to the maternal CD4+ cell count (\( r = -0.420, p = 0.023 \)); this was true also for the cytolytic isotypes (IgG1: \( r = -0.429, p = 0.020; \) IgG3: \( r = -0.447, p = 0.015 \) (Fig. 2)). No association with maternal viroimmunological parameters was detected for IgG2 or IgG4. At the following time points (months 6 and 24) no significant association between maternal CD4 cell count and the HEU infants IgGs levels were detected. Neither the duration of maternal ART in pregnancy nor the infant’s birth weight was associated with the IgGs maturation process during the study (data not shown).

At 6 months, at the end of the breastfeeding period, a non significant decline in total IgG (\( -2.1 \text{ g/l}, p = 0.191 \)), IgG1 and IgG4 levels (\( -1.12 \text{ g/l}, p = 0.496 \) and \( -0.04, p = 0.100 \), respectively) was observed in infants. On the contrary, both IgG2 and IgG3 subclasses significantly increased during the first 6 months of life (IgG2 = + 0.24 g/l, IQR: 0.06 – 0.46, \( p = 0.027 \); IgG3 = + 0.054, IQR: 0.09–0.34, \( p = 0.002 \)).

From month 6 to month 24 the total IgG levels significantly increased (median increase of + 4.03 g/l, IQR: 1.01–7.4, \( p = 0.005 \)). A similar trend was observed for IgG1 (\( + 3.2 \text{ g/l, IQR: 0.7–5.6, } p = 0.004 \)). IgG2 showed a median increase of 0.19 g/l (\( p = 0.020 \)), while IgG3 levels remained similar to those found at 6 months and IgG4 showed a non-significant increase (\( p = 0.371 \)). The dynamics of IgGs changes are reported in Fig. 1a. In the Figure, the values of the present study are compared to the IgGs values obtained in recent studies on healthy infants of different ethnic origins [19, 21–23]. With respect to the values reported in the literature, HEU infants in our study at one-month of age had a high level of IgG and IgG1 and low levels of IgG2. IgG3 and IgG4 levels were within the ranges reported. Although the longitudinal changes in IgGs seemed to follow the physiological trend observed in healthy populations, at 24 months the total IgG and IgG1 levels in HEU infants of our cohort were higher with respect to the reported values. The ART interruption in mothers with more than 350 CD4+ cell/μl count at 6 months postpartum

Table 1 Maternal and infant characteristics. Values are expressed as medians with interquartile range or percentage

| Mothers                          |   |   |
|----------------------------------|---|---|
| N.                               | 30|   |
| Age (years)                      | 28.0 (23.8–31.3) |   |
| WHO stage I, II, III (%)          | 70/23.3/6.7 |   |
| CD4+ cell count (cells/μl)       | 322 (211–469) |   |
| CD4 < 350 cells/μl (n, %)        | 16 (55.2) |   |
| HIV-RNA (log copies/ml)          | 3.92 (3.07–4.43) |   |
| Weeks of ART in pregnancy        | 10 (5.7–14) |   |

| Infants                          | 3 | 3 |
|----------------------------------|---|---|
| weight at birth* (kg)            | 3.35 (3.06–3.53) |   |
| low birth weight† n              | 3 |   |
| gender (female, n %)             | 13, 43.3% |   |

*Neonatal weight was recorded within 15 days from delivery
†The neonatal weight < 2500 g was considered low birth weight [23]
did not impact IgGs development in 24 month-old infants (data not shown).

The dynamics of changes in IgG isotype proportions out of the total IgG level are reported in Fig. 3. It can be seen that the proportions of the different isotypes did not change significantly during the course of the study and that at 24 months of age HEU children still have an overrepresentation of IgG1 (more than 80%), with IgG2 accounting for less than 8% of the total IgG.

**IgM and IgA changes during 24 months**

IgM and IgA levels were also longitudinally measured in HEU infants. Both increased significantly during the study period (Table 2). In Fig. 1 longitudinal values of IgM and IgA in HEU infants of our cohort in relation to IgM and IgA levels observed in healthy infants of different ethnic origins [19, 22, 24].

**IgG levels in infants infected with HIV during the 24 months**

During the SMAC study, only 8 infants acquired HIV infection [20]. In the present study, we could only analyze the incomplete IgG profiles of 5 of them. Two infants (Pt1 and Pt2) acquired the HIV infection between 3 and 6 months. In both cases, IgG levels at 6 months, during the acute phase of the infection, were very high (30.5
and 16.9 g/dl in Pt1 and Pt2, respectively). Moreover, they presented an abnormal distribution of subclasses: IgG1, which in their HEU counterparts represented about 90% of the total IgG, in these two infants accounted for 44.6 and 57.1% of the total IgG, respectively (Fig. 4). Abnormalities in the other subclasses were less evident.

At 24 months samples were available for only 4 HIV+ children. Although under ART, the median level of total IgG in these children was 21.1 g/l (range: 12.8–28.5), 3 out of 4 had hypergammaglobulinemia (total IgG over 15 g/l), and the isotype distribution was similar to those observed in HIV-infected adults: IgG1 = 18.9 g/l, range: 12.2–26.6; IgG2 = 0.97 g/l, range: 0.72–1.24; IgG3 = 0.72 g/l, range: 0.53–1.39; IgG4 = 0.053 g/l, range: 0.03–0.16.

**Discussion**

In our cohort, the HIV-exposed uninfected infants were born with high IgG levels with an over-representation of

| Table 2 Characteristics of 30 HIV-exposed uninfected infants at the time points of the study. Values are expressed in median and interquartile range |
|----------------------------------------|--------------------------|--------------------------|
| Month 1 (n = 30)                       | Month 6 (n = 15)          | Month 24 (n = 30)         |
| Weight (kg)                            | 4.100 (3.500–4.300)      | 7.300 (6.405–8.490)      | 10.0 (9.6–11.2) |
| Hb (g/dl)                              | 11.3 (10.6–12.1)         | 10.0 (9.38–10.63)        | 10.2 (9.55–10.93) |
| IgG (g/dl)                             | 8.48 (7.57–9.15)         | 6.80 (6.17–7.78)         | 12.3 (10.2–13.8) |
| IgG1 g/l                               | 7.27 (6.65–8.18)         | 5.59 (5.56–7.25)         | 10.1 (8.68–11.53) |
| %                                      | 86.6 (84.1–88.3)         | 88.5 (86.9–91.9)         | 86.7 (84.0–88.1) |
| IgG2 g/l                               | 0.52 (0.46–0.65)         | 0.68 (0.55–0.96)         | 0.87 (0.68–1.12) |
| %                                      | 6.65 (5.5–9.03)          | 10.0 (9.0–12.3)          | 7.4 (6.2–9.5)   |
| IgG3 g/l                               | 0.24 (0.19–0.35)         | 0.463 (0.32–0.52)        | 0.400 (0.324–0.602) |
| %                                      | 3.2 (2.4–3.8)            | 6.01 (4.5–6.9)           | 3.3 (2.8–4.9)   |
| IgG4 g/l                               | 0.06 (0.03–0.13)         | 0.032 (0.02–0.05)        | 0.061 (0.038–0.09) |
| %                                      | 0.84 (0.48–1.38)         | 0.50 (0.29–0.60)         | 0.58 (0.36–0.82) |
| IgGA (g/dl)                            | 0.11 (0.08–0.16)         | 0.41 (0.32–0.51)         | 0.87 (0.63–1.00) |
| IgM (g/dl)                             | 0.42 (0.27–0.52)         | 0.75 (0.47–0.92)         | 0.86 (0.75–1.12) |

![Fig. 2](image-url) Correlation between maternal CD4+ cell count and immunoglobulins levels in 1-month old HEU infants of the study. Blue circle: total IgG; red circle: IgG1, green circle IgG4.
the IgG1 and a low IgG2 concentration. At 2 years of life, the HEU infants still had high levels of total IgG and IgG1 and a substantial disproportion in isotype distribution with respect to reference intervals of same-aged infants. It has to be noted that, to contextualize our findings, the evaluation of IgGs maturation in our cohort was made using reference values from other studies on infants from different ethnic groups.

The longitudinal changes observed in our cohort in IgA and IgM, synthesized by the fetus from early intrauterine life [28], seem to present development within the physiological ranges reported by the literature.
In our study the HEU infants 1-month-old had higher total IgG and IgG1 levels with respect to reference intervals reported in other studies [19, 24–27]; this finding is not surprising since the neonatal IgG profile reflects the maternal IgG levels and distribution. In HIV infection the decline of T-cell functionality is paralleled by the hypergammaoglobulinemia and the polarization of immunoglobulins towards IgG1 subclass, indices of B-cells dysregulation [29, 30]. At the same age, however, IgG2 isotype in the HEU infants of our cohort was underrepresented. This finding can be attributable to the lowest affinity of IgG2 isotype with FcRn placental receptors (preferential transport: IgG1 > IgG4 > IgG3 > IgG2) that causes a selective and temporary impairment of IgG2 levels also in healthy neonates [2, 31]. The one-month-old HEU infants of our cohort had a more pronounced deficit with respect to the reference values. Recently, our group reported that the IgG2 deficit in HEU infants could also be attributable to the low levels of circulating IgG2 in HIV-positive pregnant women, suggesting that the low affinity with FcRn receptors of placenta together with maternal low levels could synergically contribute to the IgG2 deficit in neonates [32].

In the first 6 months of life, we observed a temporary decline in total IgG levels, associated with the waning of maternal antibodies, slowly replaced by the HEU infants IgG own production [33]. However, a different pattern was observed for the 4 IgG subclasses: while IgG1 levels showed a decline similar to that of total IgG, IgG2 and IgG3 isotypes increased, and the levels of IgG4 did not change significantly. This finding could be correlated to the role that maternal IgG could have on the neonate’s immune system maturation [34]. Many studies have indeed reported that for several vaccines, such as live attenuated, toxoid and conjugated vaccines, high titers of maternal acquired IgG inhibit the infant’s humoral immune response after infant vaccination [35]. We hypothesize that a similar mechanism could also affect the onset of the infant’s own IgG isotype production.

In our study, neither maternal viroimmunological conditions during pregnancy (CD4 count and ART duration), nor infant’s birth weight was predictive of HEU infants’ IgG maturation over time, but we cannot exclude that the small sample size could have affected the statistical analysis.

The trend we observed in IgGs development during 24 months in the HEU infants of this longitudinal study was not different from those observed in reference intervals reported in the literature; however, at 24 months the level of total IgG was almost double to the reference values, and IgG1 was overexpressed among the subclasses. IgG2 subclass levels at 24 months were slightly lower than the normality range but their proportion over the total IgG levels accounted for 7.4% of total IgG, corresponding to half of the proportion reported for healthy populations (12–19%) [19, 24, 25, 27]. The higher IgG3 levels found in our study with respect to the reference intervals were probably linked to their role in the immunological response to malaria, which is endemic in the area where the study took place [36]. In this view, it has to be considered that the exposition to endemic pathogens is considered one of the major force driving immunological maturation [37]; unfortunately, in our study, the lack of accurate diagnosis during the scheduled medical visits prevented us to determine the real impact of viral, parasitic and bacterial diseases on developing and maturation of immunoglobulin in these children.

Although this study was designed to determine the dynamics of immunoglobulins in HEU children, we had the opportunity to test the IgG levels in infants infected by HIV during breastfeeding. Two children were infected before the physiological initiation of IgG synthesis, and in both cases, at 6 months we found a significant hypergammaoglobulinemia, with values similar to those found in HIV+ symptomatic adults [38], and a strong discrepancy between the total IgG levels and the sum of subclasses levels. The nephelometric analysis revealed for both infants that the sum of the subclass measurements accounted for only 41% of the total IgG, with a partial reduction of IgG1 subclass. The result was confirmed in both cases in a repeat test. Although we cannot rule out a technical problem (i.e. reduced interaction of IgG1 protein with the IgG1 antiserum), the finding could indicate a virus interference with the production of IgG subclasses by B cells in acute infection, determining an early impairment of the B cell compartment. The finding in our study could be considered an anecdotal observation however, this topic could be investigated in larger cohorts.

The major limitation of this study is the lack of an appropriate control group (i.e. age-matched children from the same geographical area) which does not allow us to draw definite conclusions on the levels that we found. The availability of reference values in Sub-Saharan African countries remains a challenge due to many factors, including organization aspects and lack of laboratory facilities. We are aware that the use of reference values from populations of different ethnic origin and exposed to different environmental factors, can be problematic [39], but we tried to minimize the problem using reference data selected from very recent studies, in which immunoglobulin determinations were performed using the nephelometric method, which is considered the gold standard for serum protein detection with a high standard of inter- and intra-laboratory precision and reproducibility.
The low number of subjects included is another limitation of this study, although we determined the intra-individual variation over time and observed very low inter-individual variability, that did allow us to be confident with the validity of our results.

Conclusions
Here we reported the dynamics of IgG development and maturation in HEU infants, suggesting that their IgG profile at 24 months may still present anomalies (mainly represented by hypergammaglobulinemia and low IgG2 levels) probably as a consequence of the early-life exposure to maternal HIV-related immune alterations.

In our study, performed before the adoption of the Option B+ strategy, we found a significant association between a low maternal CD4+ cell count and the levels of IgG in neonates, confirming the impact that compromised viero-immunological maternal conditions could have on the transplacental passage of IgG in neonates [2, 14, 40]. The women of this study received only a median of 10 weeks of ART during pregnancy, a duration that was inadequate to restore the HIV-related maternal immunological dysfunctions which can deeply impact neonates’ health. Future studies will determine if these anomalies in infants may be corrected by the adoption of the current strategy of universal and long-life anti-retroviral therapy administration.

Abbreviations
HIV: Human immunodeficiency virus; HEU: HIV exposed uninfected; IgG: Immunoglobulin; CMR: Child/maternal ratio

Acknowledgments
We thank Alessandra Mattei and Stefania Donnini for providing secretarial help, Marco Mirra, Massimiliano Di Gregorio, Stefano Lucattini and Luca Facili for IT support and to Ferdinando Costa and Patrizia Cocco, for technical support. We are grateful to Riccardo d’Amico for the precious technical support with BN ProSpec® System Analyzer.

Authors’ details
SB, CMG, MA, RA, MG: National Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. GL, SO: Department of Biomedicine and Prevention, University of Rome Tor Vergata, via Montpellier 1, 00133 Rome, Italy. FC: Department of Biomedicine and Prevention, University of Rome “S. Eugenio”, via Montpellier 1, 00161 Rome, Italy. GL, SO: Department of Human Sciences, LUMSA University, Via Traspontina 21, 00193 Rome, Italy.

Authors’ contributions
SB, MG: conception and study design, analysis and interpretation of data and manuscript writing. CMG, RA MA: monitoring of data collection and design of laboratory analysis. HI, RL: JBS: supervision and data collection at the clinical sites. GL, FC, SO and MCM: assistance in the design and the proposal development, revision of analysis and subsequent drafts of the paper. All authors read and approved the final manuscript.

Funding
This work was supported by a grant from the Ministry of Health, Rome, Italy (grant no. 3C04/1), and by Esther-Italy, Ministry of Health (grant no. 9 M34). The funders had no additional role in the design, data management, and analysis, nor in the interpretation of the data and decision to submit the manuscript for publication.

Availability of data and materials
Dataset of the current study is available on reasonable requests.

Ethics approval and consent to participate
Ethics approval was received by the National Health Research Committee, Ministry of Health, Lilongwe, Malawi (approval number #486). Written and verbal consent was obtained from all individual participants included in the study before data collection. For minors consent was obtained from their mothers.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1National Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. 2Department of Biomedicine and Preventio, University of Rome Tor Vergata, Rome, Italy. 3Saint Camillus International University of Health Sciences, Rome, Italy. 4DREAM Program, Community of S. Eugidio, Blantyre, Malawi. 5Department of Human Sciences, LUMSA University, Rome, Italy.

Received: 20 January 2020 Accepted: 16 April 2020
Published online: 23 April 2020

References
1. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofoetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36(5):248–55.
2. Palmeira P, Quinello C, Silvera-Lessa AL, Zago CA, Cameiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:986564.
3. Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmunity diseases. New England J Med 2001;345(18):1331–5.
4. Tobin NH, Aldrovandi GM. Immunology of pediatric HIV infection. Immunol Rev. 2013;254(1):134–69.
5. Marques AH, D’Connor TG, Roth C, Sussel E, Bjørke-Monsen AL. The influence of maternal prenatal and early childhood nutrition and maternal prenatal stress on offspring immune system development and neurodevelopmental disorders. Front Neurosci. 2013;7:120.
6. Yockey LJ, Iwasaki A. Interferons and Proinflammatory cytokines in pregnancy and fetal development. Immunol Res. 2018;49(3):397–412.
7. MacGillivray DM, Kollmann TR. The role of environmental factors in modulating immune responses in early life. Front Immunol. 2014;5:434.
8. Pfeifer C, Bunders MJ. Maternal HIV infection alters the immune balance in the mother and fetus; implications for pregnancy outcome and infant health. Curr Opin HIV AIDS. 2016;11(2):138–45.
9. Ruck C, Reikie BA, Marchant A, Kollmann TR, Kakkar F. Linking susceptibility to infectious diseases to immune system abnormalities among HIV-exposed uninfected infants. Front Immunol. 2016;7:310.
10. Slogrove AJ, Goetgebuer T, Cotton MF, Singer J, Bettinger JA. Pattern of infectious morbidity in HIV-exposed uninfected infants and children. Front Immunol. 2016;7:164.
11. Fouda GG, Martinez DR, Swamy GK, Permar SR. The impact of IgG transplacental transfer on early life immunity. Immunohorizons. 2018;2(2):14–25.
12. Abu-Raya B, Smolen KK, Willems F, Kollmann TR, Marchant A. Transfer of maternal antimicrobial immunity to HIV-exposed uninfected newborns. Front Immunol. 2016;7:338.
13. Abu-Raya B, Kollmann TR, Marchant A, MacGillivray DM. The immune system of HIV-exposed uninfected infants. Front Immunol. 2016;7:383.
14. Cumberland P, Shulman CE, Maple PA, Bulmer JN, Domann EK, Kauwondo K, et al. Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis. 2007;196(4):550–7.
15. Sanz-Ramos M, Manno D, Kapambwe M, Ndumba I, Munsoda KG, Bates M, et al. Reduced poliovirus vaccine neutralising-antibody titres in infants with maternal HIV-exposure. Vaccine. 2013;31(3):2042–9.
